Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-17
2007-07-17
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S339000, C514S414000, C514S419000, C546S146000, C546S277400, C548S455000, C548S491000
Reexamination Certificate
active
11002131
ABSTRACT:
Selectively BRS-3-agonistic compounds of formula Iwherein A1, A2, A3, R1, R2, R3, Ar1, Ar2, Ar3, m and n have the meanings given in the description, and also pharmaceutical compositions containing these compounds and a process for the preparation of compounds of Formula I are described.
REFERENCES:
patent: 5153226 (1992-10-01), Chucholowski et al.
patent: 5200408 (1993-04-01), Bru-Magniez et al.
patent: 5565568 (1996-10-01), Cho et al.
patent: 5773441 (1998-06-01), Hipskind et al.
patent: 6194437 (2001-02-01), Horwell et al.
patent: 6307017 (2001-10-01), Coy et al.
patent: 2002/0028799 (2002-03-01), Naylor et al.
patent: 2002/0055759 (2002-05-01), Shibuya
patent: 2002/0058606 (2002-05-01), Gonzalez et al.
patent: 2002/0169101 (2002-11-01), Gonzalez et al.
patent: 2002/0177689 (2002-11-01), Benson et al.
patent: 2003/0119714 (2003-06-01), Naylor et al.
patent: 2004/0023862 (2004-02-01), Smart et al.
patent: 2004/0039198 (2004-02-01), Bender et al.
patent: 2004/0087561 (2004-05-01), Gonzalez et al.
patent: 2004/0110768 (2004-06-01), Higginbottom et al.
patent: 2004/0116440 (2004-06-01), Higginbottom et al.
patent: 0 415 413 (1991-03-01), None
patent: WO 92/02244 (1992-02-01), None
patent: WO 95/00542 (1995-01-01), None
patent: WO 97/06803 (1997-02-01), None
patent: WO 98/07718 (1998-02-01), None
patent: WO 98/31214 (1998-10-01), None
patent: WO 01/68120 (2001-09-01), None
patent: WO 02/40008 (2002-05-01), None
patent: WO 02/40022 (2002-05-01), None
patent: WO 02/40069 (2002-05-01), None
patent: WO 02/40468 (2002-05-01), None
patent: WO 02/40469 (2002-05-01), None
patent: WO 02/40475 (2002-05-01), None
Weber et al., “Systemic Optimization of a Lead-Structure Identifies for a Selective Short Peptide Agonist for the Human Orphan Receptor BRS-3,” J. of Peptide Science, vol. 8, pp. 461-475 (2002).
Weber et al., “Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3#,” J. Med. Chem., 46(10), pp. 1918-1930 (2003).
Barbara Dorner, et al., “Preparation of Carboxy-Modified Peptide Fragments using Alkyoxybenzaldehyde Resins”, Peptides, 1998, pp. 90 and 91, Akadémiai Kiadó, Budapest, 1999.
Achim Fleischmann, et al., “Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases”, Laboratory Investigation, Dec. 2000, pp. 1807-1817, vol. 80, No. 12, The United States and Canadian Academy of Pathology, Inc.
Valentin Gorbulev, et al., “Organization and Chromosomal Localization of the Gene for the Human Bombesin Receptor Subtype Expressed in Pregnant Uterus” FEBS Letters, 1994, pp. 260-264, vol. 340, Federation of European Biochemical Societies.
Samuel A. Mantey, et al., “Rational Design of a Peptide Agonist that Interacts Selectively with the Orphan Receptor, Bombesin Receptor Subtype 3*”, Sep. 2000, pp. 9219-9229, JBC Papers in Press, Published Dec. 8, 2000.
Hiroko Ohki-Hamazaki, et al., “Mice Lacking Bombesin Receptor Subtype-3 Develop Metabolic Defects and Obesity”, Letters to Nature, Nov. 1997, pp. 165-169, vol. 390.
Baodong Sun, “Presence of Receptors for Bombesin/Gastrin-Releasing Peptide and mRNA for Three Receptor Subtypes in Human Prostate Cancers”, The Prostate, 2000, pp. 295-303, vol. 42, Wiley-Liss, Inc.
Dirk Weber, et al., “Design of Selective Peptidomimetric Agonists for the Human Orphan Receptor BRS-3#”, Apr. 15, 2003, pp. 1918-1930, vol. 46, No. 10, American Chemical Society.
Kazuyuki Yamada, et al., “Differential Effects of Social Isolation upon Body Weight, Food Consumption, and Responsiveness to Novel and Social Environment in Bombesin Receptor Subtype-3 (BRS-3) Deficient Mice”, Physiology & Behavior, 2000, pp. 555-561, vol. 68, Elsevier Science Inc.
A. Flörsheimer, et al., “Solid-Phase Synthesis of Peptides with the Highly Acid-Sensitive HMPB Linker”, Peptides, 1990, pp. 131-133, ESCOM Science Publishers B.V., Published 1991.
Von Rudolf Gretler, et al., The Mass Spectral Retro-Diels-Alder-Reaction: 1,2,3,4-Tetrahydroisoquinoline and 1,2,3,4-Tetrahydronaphthalina (Tetraline) (1978).
Samuel A. Mantey, et al., Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates that has a Unique Pharmacology Compared with Other Mammalian Bombesin Receptors, The Journal of Biological Chemistry, Oct. 10, 1997, pp. 26062-26071, vol. 272, No. 41.
Tapas K. Pradhan, et al., “Identification of a Unique Ligand which has High Affinity for All Four Bombesin Receptor Subtypes”, European Journal Of Pharmacology, 1998, pp. 275-287, vol. 343, Elsevier Science B.V., Published Nov. 14, 1997.
Dirk Weber, et al., “Systemic Optimization of a Lead-Structure Identifies for a Selective Short Peptide Agonist for the Human Orphan Receptor BRS-3”, Journal of Peptide Science, 2002, pp. 461-475, vol. 8, European Peptide Society and John Wiley & Sons, Ltd.
James M. Wu, et al., “Discovery of High Affinity Bombesin Receptor Subtype 3 Agonists”, Molecular Pharmacology, 1996, pp. 1355-1363, vol. 50, The American Society of Pharmacology and Experimental Therapeutics.
Kazuyuki Yamada, et al., “Hyperresponsiveness to Palatable and Aversive Taste Stimuli in Genetically Obese (Bombesin Receptor Subtype-3-Deficient) Mice”, Physiology & Behavior, 1999, pp. 863-867, vol. 66, No. 5, Elsevier Science Inc., PII S0031-9384(99)00032-3.
Zahra Fathit§, et al., “BRS-3: A Novel Bombesin Receptor Subtype Selectively Expressed in Testis and Lung Carcinoma Cells”, The Journal of Biological Chemistry, Mar. 15, 1993, pp. 5979-5984, vol. 268, No. 8, Published Sep. 30, 1992.
Valentin Gorbulev, et al., “Molecular Cloning of a New Bombesin Receptor Subtype Expressed in Uterus During Pregnancy”, European Journal of Biochemistry, 1992, pp. 405-410, FEBS 1992.
Antonello Mai, et al., “5-Alkyl-2-(Alkylthio)-6-(2,6-Dihalophenylmethyl)-3,4-Dihydropyrimidin-4(3H)-c Novel Potent and Selective Dihydro-Alkoxy-Benzyl-Oxopyrimidine Derivative”, J. Med. Chem., 1999, pp. 619-627, vol. 42, American Chemistry Society, Published Feb. 5, 1999.
Christopher J. Moody, et al., “Diels-Alder Reactivity of Pyrano[4,3-b]indol-3-ones, Indole 2,3-Quinodimethane Analogues”, J. Chem. Soc., 1990, pp. 673-679.
Baodong Sun, et al., “The Presence of Receptors for Bombesin/GRP and mRNA for Three Receptor Subtypes in Human Ovarian Epithelial Cancers”, Regulatory Peptides, 2000, pp. 77-84, vol. 90, Elsevier Science B.V.
K. Yamada, et al., “Role of Bombesin (BN)-like Peptides/Receptors in Emotional Behavior by Comparison of Three Strains of BN-like Peptide Receptor Knockout Mice”, Molecular Psychiatry, 2002, pp. 113-117, vol. 7, Nature Publishing Group.
Antel Jochen
Berger Claudia
Heinrich Timo
Kessler Horst
Weber Dirk
Crowell & Moring LLP
Freistein Andrew B.
Saeed Kamal A.
Solvay Pharmaceuticals GmbH
LandOfFree
Non-peptidic BRS-3 agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-peptidic BRS-3 agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-peptidic BRS-3 agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774969